<DOC>
	<DOCNO>NCT01673919</DOCNO>
	<brief_summary>This long-term , open-label extension study evaluate safety RoActemra/Actemra ( tocilizumab ) patient polyarticular-course juvenile idiopathic arthritis complete WA19977 core study . Patients continue receive RoActemra/Actemra 8 mg/kg intravenously every 4 week . Anticipated time study treatment 104 week .</brief_summary>
	<brief_title>A Long-Term Extension Study RoActemra/Actemra ( Tocilizumab ) Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Patients complete visit 33 ( week 104 ) WA19977 study may benefit study drug treatment accord investigator 's assessment Patients receive first RoActemra/Actemra infusion study Week 8 visit late Females childbearing potential male female partner childbearing potential must agree use effective contraception define protocol Patients , accord investigator judgment , satisfactory benefit RoActemra/Actemra therapy within WA19977 Treatment investigational agent since last administration study drug core study WA19977 Patient develop autoimmune rheumatic disease overlap syndrome permitted polyarticularcourse Juvenile Idiopathic Arthritis ( JIA ) subset : rheumatoid factor positive negative JIA extend oligoarticular JIA Patient pregnant , lactating , intend become pregnant study 12 week last administration study drug Any significant concomitant disease medical surgical condition History significant allergic infusion reaction prior biologic therapy Currently active primary secondary immunodeficiency Any infection contraindication RoActemra/Actemra therapy accord investigator judgment Inadequate hepatic , renal bone marrow function</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>